#HerHealth2026: Updates in
Breast & Gynecologic
Cancer Therapeutics
Women’s Oncology Summit
Oct 9–10, 2026
10 AMA PRA Category 1 Credits10 MOC Credits (ABIM)
10 Contact Hours
AMA Conference CenterTimes Square, Manhattan
1601 Broadway, New York, NY 10019, USA
About #HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics
#HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics is a premier hybrid CME/CE-accredited conference dedicated to advancing clinical excellence in the prevention, diagnosis, treatment, and survivorship care of cancers affecting women. Taking place on October 9 -10, 2026, in New York City, this educational event will bring together oncologists, gynecologic oncologists, hematologist-oncologists, surgeons, advanced practice providers (APPs), nurses, researchers, and other multidisciplinary healthcare professionals for an immersive learning experience focused on the rapidly evolving field of women’s oncology.
The conference will feature expert-led presentations, evidence-based clinical updates, interactive case discussions, and multidisciplinary perspectives on the latest advances in breast and gynecologic cancer care. Key educational topics will include breast cancer, ovarian cancer, endometrial cancer, cervical cancer, and rare gynecologic malignancies, with a focus on emerging treatment paradigms, biomarker-driven decision-making, precision medicine, antibody-drug conjugates (ADCs), immunotherapy, and novel targeted therapies. Attendees will also explore the growing impact of artificial intelligence, molecular diagnostics, genomic profiling, and innovative technologies that are reshaping oncology practice and improving patient outcomes.
Designed to bridge the gap between research and real-world clinical application, HerHealth2026 provides a collaborative platform for knowledge exchange, professional networking, and practical learning. Participants will gain actionable insights into current treatment challenges, evolving standards of care, and future directions in women’s oncology, helping them deliver more personalized, evidence-based care across diverse patient populations. Whether attending in person or virtually, healthcare professionals will leave equipped with the latest strategies and innovations needed to optimize outcomes for women affected by cancer.
Welcome Message from Our Chair
As Chair of #HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics, I am pleased to invite you to join us in New York City on October 9–10, 2026, for a collaborative educational program focused on advancing the care of women with cancer.
This conference will bring together oncology specialists, researchers, and multidisciplinary healthcare professionals to review the latest clinical advances in breast cancer and gynecologic malignancies, including ovarian, endometrial, cervical, and rare gynecologic cancers. The program will highlight evolving strategies in biomarker-guided treatment selection, targeted therapies, immunotherapy, antibody-drug conjugates, and the growing role of artificial intelligence in oncology, while addressing key clinical challenges in translating emerging evidence into real-world practice.
We look forward to welcoming you to this important forum dedicated to improving clinical decision-making and outcomes for women with cancer.
Ursula A. Matulonis, MD
Conference Chair
Chief, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Conference Highlights
Networking
#HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics provides an opportunity to connect with leading experts in breast and gynecologic oncology, including oncologists, researchers, and multidisciplinary healthcare professionals. Engage in meaningful discussions, exchange clinical insights on emerging therapies, biomarker-driven treatments, and precision oncology, and build collaborations that support innovation and improved outcomes for women with cancer.
Session Insights
Explore focused sessions covering key advances in breast cancer and gynecologic malignancies, including ovarian, endometrial, cervical, and rare cancers. #HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics will feature expert-led discussions on biomarker-driven therapies, antibody-drug conjugates, targeted treatments, immunotherapy, and emerging technologies such as artificial intelligence in oncology, highlighting clinical evidence and practical strategies that can be integrated into patient care.
Target Audience
#HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics welcomes a multidisciplinary audience involved in the care of women with cancer, including medical oncologists, gynecologic oncologists, hematologist-oncologists, OB/GYN physicians, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, researchers, and other healthcare professionals committed to advancing the diagnosis, treatment, and management of breast and gynecologic malignancies.
#HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics is accredited by eMedEd, an approved provider of continuing medical education by the Accreditation Council for Continuing Medical Education (ACCME) and continuing education by the California Board of Registered Nursing (CBRN), offering CME for physicians and CE for nurses. This program is accredited for 10 AMA PRA Category 1 Credits™ and 10 ABIM MOC Credits for physicians and 10 contact hours for nurses.
Conference Topics
Conference Agenda
Day 1 - Friday, October 9, 2026 (Half Day)
BREAST CANCER
Time (EST)TopicsSpeakers
12:00 pm - 1:00 pmRegistration | Virtual Platform Opens
1:00 pm - 1:15 pmWelcome and Opening RemarksConference Chair: Ursula Matulonis, MD
1:15 pm - 1:45 pmPLENARY SESSION
Targeting Homologous Recombination Deficiency in Breast CancerSusan Domcheck, MD
University of Pennsylvania
1:45 pm - 2:45 pmThe Use of ER+ Directed Therapies for Breast Cancer:
Current Therapeutic Options and What Is Ahead?Erica Mayer, MD
Dana-Farber Cancer Institute
2:45 pm - 3:00 pmBreak
3:00 pm - 4:00 pmHER2-Directed Therapies for Breast CancerShanu Modi, MD
Memorial Sloan Kettering Cancer Center (MSKCC)
4:00 pm - 4:45 pmTriple-Negative Breast Cancer in the Immunotherapy and ADC Era
Biomarkers, Resistance, and Toxicity ManagementTiffany Traina, MD
Memorial Sloan Kettering Cancer Center (MSKCC)
4:45 pm - 5:15 pmBreast Cancer Tumor BoardLeader of the Tumor Board: Dr. Erica Mayer
Faculty: All faculty of the afternoon
5:30 pm - 6:30 pmSatellite Symposium (Dinner Included)
Day 2 - Saturday, October 10, 2026 (Full Day)
GYNECOLOGIC ONCOLOGY
Time (EST)TopicsSpeakers
7:00 am - 8:00 amBreakfast | Virtual Platform Opens
8:00 am - 8:45 amOVARIAN CANCER
Current and Emerging Therapies for Newly Diagnosed Ovarian Cancer
Frontline Therapy, Maintenance Strategies, and Early ResistanceDmitriy Zamarin, MD
Icahn School of Medicine at Mount Sinai
8:45 am - 9:30 amOVARIAN CANCER
Increasing Options for Patients With Platinum-Resistant Ovarian Cancer
Evidence-Based Systemic Options and Therapeutic LimitsUrsula Matulonis, MD
Dana-Farber Cancer Institute
9:30 am - 10:15 amENDOMETRIAL CANCER
Molecular Classification, Treatment Implications and Discuss New Treatments for Newly Diagnosed Cancer as Well as Recurrent CancerUrsula Matulonis, MD
Dana-Farber Cancer Institute
10:15 am - 10:30 amBreak
10:30 am - 11:15 amCERVICAL CANCER
Cervical Cancer in the Immunotherapy Era
Current Standards and Emerging RegimensBhavana Pothuri, MD
NYU Langone Health
11:15 am - 12:00 pmGynecologic Oncology Tumor BoardModerated by Dr. Matulonis
Faculty: All Gyn Onc Faculty
12:00 pm - 12:45 pmLunch
12:45 pm - 1:30 pmCROSS-CUTTING & SPECIAL TOPICS
Rare Gynecologic Malignancies
Vulvar, Vaginal, and Uncommon Female CancersRachel Grisham, MD
Memorial Sloan Kettering Cancer Center (MSKCC)
1:30 pm - 2:15 pmBiomarkers in Women's Cancers
Clinical Utility, Limitations, and ImplementationBhavana Pothuri, MD
New York University (NYU)
2:15 pm - 3:00 pmAdverse Event Management in Modern Oncology
IO, ADC, and Targeted Therapy ToxicitiesVicky Makker, MD
Memorial Sloan Kettering Cancer Center (MSKCC)
3:00 pm - 3:30 pmCutting Through the Hype: Real-World Uses of AI in Breast and Gynecologic OncologyConstance Lehman, MD, PhD
Clairity, Inc.
3:30 pm - 3:45 pmBreak
3:45 pm - 4:15 pmClosing Plenary: Translating Evidence Into PracticeUrsula Matulonis, MD
Dana-Farber Cancer Institute
4:30 pm - 5:30 pmSatellite Symposium
Esteemed Speakers
Brings Together Highly Esteemed and Dynamic Speakers
Conference Registration
| Participants | Early Bird Fee Before June 30, 2026 | Standard Fee On/Before October 9, 2026 |
|---|
For assistance with group registrations,or any other inquiries, please contact us at
oncology@emedevents.com
+1(800) 828 - 2059
* You'll receive an itemized receipt via email.
Our team will respond within 24 hours.
Conference Venue
AMA Executive Conference Center
1601 Broadway, Times Square, Manhattan, New York, USA
#HerHealth2026 FAQs
Quick answers about attendance, credits, access, and conference logistics for the breast and gynecologic cancer therapeutics program.
Contact Us at contact@emedevents.com
Organized by
Marketing Partner
